Long-Term Investor Stock Analysis of Merck (MRK)Read More »
This content is restricted to site members. If you are an existing user, please log in. New users may register below.
Long-Term Investor Stock Analysis of Merck (MRK)
Views: 251 Date: 2025-12-16 Merck is a global pharmaceutical company focused on oncology, vaccines, animal health, and specialty medicines. Its earnings power is driven primarily by high margin patented drugs, most notably Keytruda, supported by a diversified late-stage pipeline. QuestionAnswerIs the business model simple and sustainable?Yes. Merck invests heavily in R&D, protects intellectual property, commercializes patented drugs, and reinvests cash flows into pipeline expansion. This model is capital intensive but structurally durable.Does the company have a durable competitive advantage (moat)?Yes. Regulatory barriers, patents, brand trust, and scale in clinical trials create a very wide moat. These advantages are difficult and …
